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did not have thyroid or liver function test, respectively in
the previous 6 months. 
CONCLUSIONS: Patient safety from amiodarone toxic
effects is of high concern. Despite national guidelines and
a high prevalence of use, we found that over half of the
patients receiving amiodarone therapy were not being
monitored appropriately for toxicity. We conclude that
there is need for a formal amiodarone monitoring
program in this setting. We have designed and are testing
a chart reminder system to address this deﬁcit.
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OBJECTIVES: Clinical trials have demonstrated that
drug therapy can reduce osteoporosis-related fracture risk
in women over 50 years by up to 40% provided they 
consistently take their medication for a year or more.
Non-adherence with drug therapies not only limits the
drugs’ effectiveness, but could also be associated with a
higher fracture risk. The objective of this study was there-
fore to estimate fracture risk in relation to adherence with
osteoporosis medication in actual practice. 
METHODS: Demographic, prescription drug use, physi-
cian services and hospitalization information for females
with osteoporosis who were dispensed an osteoporosis
medication between 1996 and 2001 (entry date deﬁned
as ﬁrst dispensing in this period) was obtained from the
Saskatchewan Health data ﬁles. Adherence to treatment
was deﬁned as drug available to cover 80% of the time.
Subsequent fractures were identiﬁed via hospitalizations
or physician contacts with a relevant diagnostic or pro-
cedure code. The risk of fractures in relation to adherence
was examined using a Cox proportional hazards model
with time-dependent covariates. The impact of other
patient characteristics, including age, having suffered a
prior fracture, prior use of osteoporosis medication and
steroids, was also examined. 
RESULTS: 11,249 women suffering from osteoporosis
were identiﬁed with a mean age at the time of the index
prescription of 68.4 years and average follow-up of 2.3
years with a fracture rate of 4.5% per year. Patients 
who adhered experienced a 16% lower fracture rate. The
effect of adherence was maintained after controlling for
other patient characteristics that independently predict
the fracture rate, including interactions. 
CONCLUSIONS: These results indicate that improving
adherence in actual practice will signiﬁcantly decrease the
osteoporosis-related fracture risk.
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OBJECTIVES: To investigate under which circumstances
statins can be considered cost-effective in primary 
prevention of CHD, and to identify the most sensitive
parameters. 
METHODS: A Markov Model is used to tackle the
research question for the health insurance and the social
insurance in Germany. Life years gained are chosen as
effectiveness parameter. Mortality is based on the concept
of Gompertzian analysis, linking mortality rates for
persons with and without coronary heart disease (CHD).
Costs components comprise of prevention costs, costs in
the life years gained, national insurance contributions and
avoided costs for CHD-treatment. Age and gender spe-
ciﬁc costs and expenditures for health states are estimated
from data of the social insurance including pension 
payments. CHD-risk estimates are primarily based on
Framingham risk equations, but an alternative method
using current CHD-mortality data is used as well. 
RESULTS: With yearly Statin prices of 300 € (€/$ = .9)
and a relative CHD-risk reduction of 28%, statin treat-
ment for a 50 year old male with a yearly CHD-risk of
1,5% would cost between 23,000 € and 26,000 € per life
year gained for the social insurance and 13,000 € and
16,000 € for the health insurance. For higher CHD-risks
statin treatment gets more cost-effective. At a given value
of CHD-risk, cost-effectiveness is generally better for
younger patients. The most sensitive parameters are the
yearly statin prices und the relative risk reduction. Per 
rise in statin prices of 100 €, cost-effectiveness would
increase between 5,000 € and 7,000 € per life year gained
depending on age and gender. Avoided CHD-treatment
costs, however, have only a minor impact on the 
cost-effectiveness-ratio. 
CONCLUSIONS: Treatment guidelines for CHD preven-
tion incorporating cost-effectiveness considerations are
vulnerable to future statin pricing after the soon fall of
protection by patent. Correct risk estimation remains one
important objective in targeting resources for primary
CHD-prevention.
CV6
COMPARING RECENT CARDIOVASCULAR
MEDICATIONS USING AN NNT MODEL
Caro J1, Ishak K2, Caro I2, Migliaccio-Walle K1
1Caro Research Institute, Concord, MA, USA; 2Caro Research
Institute, Dorval, QC, Canada
The number needed to treat (NNT) has been promoted
as a tool for helping decision makers but valid compari-
